Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 5, 2017-- $12 Million Series A financing supports development of best-in-class therapy for acute migraine that incorporates novel and proprietary SNBL nasal drug delivery technology --
Satsuma Pharmaceuticals, Inc., a leader in developing best-in-class therapies to address the unmet needs of migraine sufferers, today announced the closing of a $12 million Series A financing...